Pathology: es-BC - HR positive - (neo)adjuvant (NA);
| es-BC - HR positive - (neo)adjuvant (NA) | |||
| Harbeck (TDM-1), 2017 | Harbeck (TDM1 plus ET), 2017 | ||
| trastuzumab emtansine | 1 | T1 | |
| trastuzumab emtasine plus endocrine therapy | 1 | T1 | |
| trastuzumab plus endocrine therapy | 0 | T0 | T0 |